학술논문
Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021.
Document Type
Academic Journal
Author
Woudenberg T; Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.; Pinaud L; Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France.; Garcia L; Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.; Tondeur L; Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France.; Pelleau S; Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.; De Thoisy A; Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.; Donnadieu F; Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.; Backovic M; Structural Virology Unit, Department of Virology and CNRS UMR 3569, Institut Pasteur, Université Paris-Cité, Paris, France.; Attia M; Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, Université Paris-Cité, CNRS UMR 3569, Paris, France.; Hozé N; Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris-Cité, UMR2000, CNRS, Paris, France.; Duru C; Hôpital de Crépy-en-Valois, Crépy-en-Valois, France.; Koffi AD; Hôpital de Crépy-en-Valois, Crépy-en-Valois, France.; Castelain S; Laboratoire de virologie, CHU Amiens, AGIR UR4294, UPJV, Amiens, France.; Ungeheuer MN; Clinical Investigation and Access to Research Bioresources (ICAReB) platform, Center for Translational Science, Institut Pasteur, Paris, France.; Fernandes Pellerin S; Center for Translational Science, Institut Pasteur, Paris, France.; Planas D; Virus and Immunity Unit, Department of Virology, Institut Pasteur, Université Paris-Cité, Paris, France.; Bruel T; Virus and Immunity Unit, Department of Virology, Institut Pasteur, Université Paris-Cité, Paris, France.; Cauchemez S; Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris-Cité, UMR2000, CNRS, Paris, France.; Schwartz O; Virus and Immunity Unit, Department of Virology, Institut Pasteur, Université Paris-Cité, Paris, France.; Fontanet A; PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.; Emerging Diseases Epidemiology Unit, Institut Pasteur, Université Paris-Cité, Paris, France.; White M; Infectious Disease Epidemiology and Analytics G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Paris, France.
Source
Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE
Subject
Language
English
Abstract
BackgroundThe risk of SARS-CoV-2 (re-)infection remains present given waning of vaccine-induced and infection-acquired immunity, and ongoing circulation of new variants.AimTo develop a method that predicts virus neutralisation and disease protection based on variant-specific antibody measurements to SARS-CoV-2 antigens.MethodsTo correlate antibody and neutralisation titres, we collected 304 serum samples from individuals with either vaccine-induced or infection-acquired SARS-CoV-2 immunity. Using the association between antibody and neutralisation titres, we developed a prediction model for SARS-CoV-2-specific neutralisation titres. From predicted neutralising titres, we inferred protection estimates to symptomatic and severe COVID-19 using previously described relationships between neutralisation titres and protection estimates. We estimated population immunity in a French longitudinal cohort of 905 individuals followed from April 2020 to November 2021.ResultsWe demonstrated a strong correlation between anti-SARS-CoV-2 antibodies measured using a low cost high-throughput assay and antibody response capacity to neutralise live virus. Participants with a single vaccination or immunity caused by infection were especially vulnerable to symptomatic or severe COVID-19. While the median reduced risk of COVID-19 from Delta variant infection in participants with three vaccinations was 96% (IQR: 94-98), median reduced risk among participants with infection-acquired immunity was only 42% (IQR: 22-66).ConclusionOur results are consistent with data from vaccine effectiveness studies, indicating the robustness of our approach. Our multiplex serological assay can be readily adapted to study new variants and provides a framework for development of an assay that would include protection estimates.